title: Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo.
abstract: Valproic acid (VPA) is an established drug in the long-term therapy of seizure disorders. Recently, VPA has been associated with anticancer activity, an effect thought to be mediated through the inhibition of cellular histone deacetylase 1. We investigated the effect of various doses of VPA (0, 1.2, and 5.0 mmol/L) administered either acutely or chronically on histone acetylation, p21 gene expression, androgen receptor expression, prostate-specific antigen (PSA) expression, and cell survival and proliferation in prostate cancer cell lines. We also studied the effect of chronic VPA on tumor xenograft growth in vivo. Our results show that acute treatment (3 days) VPA can increase net histone H3 acetylation and up-regulate p21, AR, and cytosolic PSA expression. Interestingly, the effects on AR and PSA are reversed with chronic treatment. In addition, acute VPA reduces cell survival but has no effect on the subsequent proliferation of surviving cells following drug withdrawal. However, when VPA is chronically administered (10-14 days) to prostate cancer cells, even lower doses of VPA result in marked decreases in the net proliferation rate, correlating with increased caspase-2 and caspase-3 activation. These effects are evident in both androgen receptor-positive (LNCaP and C4-2) and androgen receptor-negative (DU145 and PC3) prostate cancer cells. Moreover, chronic VPA treatment results in statistically significant reduction of tumor xenograft growth in vivo. We conclude that acute treatment has nominal effects on prostate cancer cell survival and proliferation, but chronic VPA results in profound decreases in proliferation, independently of androgen regulation.
authors.affiliation: Department of Urology, Shandong Provincial Hospital, Jinan, People's Republic of China.
authors.forename: Qinghua
authors.initials: Q
authors.lastname: Xia
authors.forename: Jennifer
authors.initials: J
authors.lastname: Sung
authors.forename: Wasim
authors.initials: W
authors.lastname: Chowdhury
authors.forename: Chien-Lun
authors.initials: CL
authors.lastname: Chen
authors.forename: Naseruddin
authors.initials: N
authors.lastname: Höti
authors.forename: Shabana
authors.initials: S
authors.lastname: Shabbeer
authors.forename: Michael
authors.initials: M
authors.lastname: Carducci
authors.forename: Ronald
authors.initials: R
authors.lastname: Rodriguez
mesh_terms: D000107:Acetylation / Q000187:drug effects; D000818:Animals; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004334:Drug Administration Schedule; D006657:Histones / Q000378:metabolism; D006801:Humans; D008297:Male; D015741:Metribolone / Q000494:pharmacology; D051379:Mice; D008819:Mice, Nude; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D013375:Substance Withdrawal Syndrome / Q000378:metabolism / Q000473:pathology; D014635:Valproic Acid / Q000008:administration & dosage*; D023041:Xenograft Model Antitumor Assays
chemical_list: D006657:Histones; D015741:Metribolone; D014635:Valproic Acid